300942 易瑞生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.841-20.3888.68931.66512.150
总资产报酬率 ROA (%)-0.517-14.0156.81426.20010.286
投入资产回报率 ROIC (%)-0.566-15.4777.65929.59011.415

边际利润分析
销售毛利率 (%)74.61749.92956.50671.63275.366
营业利润率 (%)-20.130-68.98714.28344.89729.059
息税前利润/营业总收入 (%)-13.938-71.06912.57745.69332.821
净利润/营业总收入 (%)-19.942-72.79812.03439.57425.323

收益指标分析
经营活动净收益/利润总额(%)107.99044.059138.51192.30095.754
价值变动净收益/利润总额(%)21.48030.4192.8203.60611.924
营业外收支净额/利润总额(%)-0.1731.404-3.395-0.089-1.571

偿债能力分析
流动比率 (X)5.7275.3873.3765.7316.735
速动比率 (X)5.4605.1582.8725.1325.947
资产负债率 (%)39.58837.42524.77717.86915.914
带息债务/全部投入资本 (%)32.28829.32710.9621.914--
股东权益/带息债务 (%)203.970234.117763.4644,870.8585,359.819
股东权益/负债合计 (%)152.318167.253303.659458.756528.428
利息保障倍数 (X)-2.26464.635-10.16754.6957.794

营运能力分析
应收账款周转天数 (天)168.561113.35747.41248.0020.000
存货周转天数 (天)322.890186.842117.164165.0690.000